viewShield Therapeutics PLC

Shield Therapeutics: 'US talks ongoing with progress being made'

Proactive Research analyst Emma Ulker says US partnering discussions at Shield Therapeutics (LON:STX) are progressing and it's a key factor given that the US represents around 70% of the US$3bn global iron replacement market.

Ulker adds that the balance sheet was recently bolstered by an US$11.4mln milestone payment from China partner ASK Pharm, providing liquidity in the months ahead to negotiate potential uncertainty owing to the coronavirus crisis.

Click here to read Emma Ulker's latest research on Shield Therapeutics

Quick facts: Shield Therapeutics PLC

Price: 95 GBX

Market: LSE
Market Cap: £111.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield Therapeutics CEO says all efforts are on securing US partner for Feraccru

Shield Therapeutics PLC’s (LON:STX) chief executive Tim Watts caught up with Proactive's Andrew Scott on the back of its 2019 results. He says that finding a US partner for its iron deficiency drug Accrufer is the top priority for 2020. Shield already has commercial agreements in Europe...

1 week, 4 days ago

2 min read